ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Thermally Gated Dual-Cascade Nanozyme for Enhanced Mild-Temperature Photothermal Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A Cascade Catalytic Nanoplatform Enabling PTT/CDT Synergistic Antibacterial and Heat-Triggered NO Release for Angiogenesis in Diabetic Wound Healing.International journal of pharmaceutics: X · 2026Article
- Wool Keratin-Engineered Manganese Nanozyme with Tumor Microenvironment-Adaptive Self-Cascade Capability for Hepatocellular Carcinoma Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy.Biomaterials research · 2026Review
- Nanosystem-Mediated Phototherapy (PDT/PTT) - Chemodynamic Therapy for Synergistic Antitumor Therapy: Strategies and Advances.International journal of nanomedicine · 2026Review
- Construction and Characterization of PDA@MnOPharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mild-temperature photothermal therapy (mPTT) is attractive for cancer treatment due to its safety and precision but is limited by heat shock protein 70 (HSP70)-mediated thermotolerance, which allows tumor cells to survive sublethal heating. Herein, a thermo-responsive cascade nanozyme system is reported (Ru-GOx-PNN) that enhances mPTT through dual suppression of HSP70. This system integrates a Ru-doped porous carbon framework that serves as both an efficient NIR photothermal transducer and a catalytic nanozyme with intrinsic peroxidase (POD)- and catalase (CAT)-like activities, immobilized glucose oxidase (GOx) to initiate metabolic oxidation and supply H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.